BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 10755319)

  • 1. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
    Lum BL; Kaubisch S; Yahanda AM; Adler KM; Jew L; Ehsan MN; Brophy NA; Halsey J; Gosland MP; Sikic BI
    J Clin Oncol; 1992 Oct; 10(10):1635-42. PubMed ID: 1403041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
    Raschko JW; Synold TW; Chow W; Coluzzi P; Hamasaki V; Leong LA; Margolin KA; Morgan RJ; Shibata SI; Somlo G; Tetef ML; Yen Y; ter Veer A; Doroshow JH
    Cancer Chemother Pharmacol; 2000; 46(5):403-10. PubMed ID: 11127945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect-response model for the time course of leukopenia with anticancer drugs.
    Minami H; Sasaki Y; Saijo N; Ohtsu T; Fujii H; Igarashi T; Itoh K
    Clin Pharmacol Ther; 1998 Nov; 64(5):511-21. PubMed ID: 9834043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.
    Lum BL; Fisher GA; Brophy NA; Yahanda AM; Adler KM; Kaubisch S; Halsey J; Sikic BI
    Cancer; 1993 Dec; 72(11 Suppl):3502-14. PubMed ID: 7902206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
    Dahl GV; Lacayo NJ; Brophy N; Dunussi-Joannopoulos K; Weinstein HJ; Chang M; Sikic BI; Arceci RJ
    J Clin Oncol; 2000 May; 18(9):1867-75. PubMed ID: 10784627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.
    Yahanda AM; Alder KM; Fisher GA; Brophy NA; Halsey J; Hardy RI; Gosland MP; Lum BL; Sikic BI
    J Clin Oncol; 1992 Oct; 10(10):1624-34. PubMed ID: 1403040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide.
    Cárcel-Trullols J; Torres-Molina F; Araico A; Saadeddin A; Peris JE
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):153-60. PubMed ID: 15114410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of grapefruit juice intake on etoposide bioavailability.
    Reif S; Nicolson MC; Bisset D; Reid M; Kloft C; Jaehde U; McLeod HL
    Eur J Clin Pharmacol; 2002 Oct; 58(7):491-4. PubMed ID: 12389073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia.
    Lacayo NJ; Lum BL; Becton DL; Weinstein H; Ravindranath Y; Chang MN; Bomgaars L; Lauer SJ; Sikic BI; Dahl GV
    Leukemia; 2002 May; 16(5):920-7. PubMed ID: 11986955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
    Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
    Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
    Malingré MM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; Ten Bokkel Huinink WW; Swart M; Lieverst J; Schellens JH
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):347-54. PubMed ID: 11345652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
    Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a limited sampling model to determine etoposide area under the curve.
    Lum BL; Lane KJ; Synold TW; Goram A; Charnick SB; Sikic BI
    Pharmacotherapy; 1997; 17(5):887-90. PubMed ID: 9324178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
    Kaul S; Srinivas NR; Igwemezie LN; Barbhaiya RH
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):15-22. PubMed ID: 8996571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.